Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quyu Zhixue Granules is a Traditional Chinese Medicine (TCM) formulation developed by Beijing Shengshi Liangfang Pharmaceutical Technology Co., Ltd. for the treatment of menorrhagia and abnormal uterine bleeding associated with blood stasis. The drug is designed based on the TCM principle of 'removing blood stasis to stop bleeding,' aiming to treat the underlying cause of excessive menstrual flow without causing further stasis. It has undergone rigorous clinical evaluation in China, including a Phase III trial (CTR20160445) specifically targeting menorrhagia of the blood stasis type. The formulation typically contains herbal extracts known for their hemostatic and pro-circulatory properties, such as Panax notoginseng and Rubia cordifolia, which work synergistically to regulate uterine blood flow and promote coagulation balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Quyu Zhixue Granules.